🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

CHLORDECONE EXPOSURE AND PROSTATE CANCER IN THE FRENCH REGION OF MARTINIIQUE

Recruitingn/aAges 18 Years - 75 YearsMaleInstitut National de la Santé Et de la Recherche …
NCT06773806 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Prostate cancer is the most common male cancer in industrialized countries, including France, with over 60,000 new cases each year, and represents the third leading cause of cancer-related death in men. The only known risk factors are age, ethnic origin and family history of prostate cancer. Indeed, there are considerable ethnic disparities in prostate cancer risk, with an incidence rate 60% higher in African-American men than in European-American men (Evans 2008). Similarly, in the French West Indies, where over 90% of the population is of Afro-Caribbean origin, the incidence of prostate cancer is twice as high as in mainland France. In 2015, the annual incidence was 88.5 cases per 100,000 in mainland France (Defossez 2021), while it was 184.1 cases per 100,000 in Guadeloupe, over the period 2008-2013 (Desloumeaux 2017), and 161.1 cases per 100,000 in Martinique, over the period 2005-2

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
INCLUSION CRITERIA To take part in this research, participants must meet the following criteria: Patients/cases : * All men newly diagnosed with Prostate Cancer in Martinique during a three-year given period in all public and private services caring for patients with Prostate Cancer, identified via multidisciplinary consultation meetings. * Male adults under 75 years of age * Resident in Martinique for at least 6 months * Histologically confirmed (inclusion possible as soon as the result is known by the urologist) * Affiliated to a social security scheme or equivalent * Have signed a free and informed consent form Biopsy-negative" controls (Group 1 controls): * All men with a negative prostate biopsy following elevated Prostate Specific Antigen (PSA) assay (\> 2.5 ng/ml) within a 3-year period in all public and private services in Martinique identified via urologists or pathologists. * Male adults under 75 years of age * Resident in Martinique for at least 6 months * Frequency matched on age (+/- 5 years) to patients * Affiliated to a social security scheme or equivalent * Signed free and informed consent PSA-negative" controls (Group 2 controls): * All men with a PSA ⩽ 2.5 ng/ml within a 3-year period and less than 3 months identified via a survey institute * Male adults under 75 years of age * Resident in Martinique for at least 6 months * Frequency matched on age (+/- 5 years) against patients * Frequency matched on socio-professional category against men of the same age in Martinique (INSEE data) NON INCLUSION CRITERIA To take part in this research, participants must not meet the following criteria: * Be subject to a legal protection measure (safeguard of justice, curatorship or guardianship). * Inability to consent because does not speak French or Creole.
💊

What it tests

  • Not listed
📍

Where

2 sites
The private clinic "Clinique Saint-Paul"
Fort-de-France, Martinique
University Hospital of Martinique (CHUM)
Fort-de-France, Martinique
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy